Evelyn E C de Jong1, Matthias Guckenberger2, Nicolaus Andratschke3, Karin Dieckmann4, Mischa S Hoogeman5, Maaike Milder6, Ditte Sloth Møller7, Tine Bisballe Nyeng8, Stephanie Tanadini-Lang9, Eric Lartigau10, Thomas Lacornerie11, Suresh Senan12, Wilko Verbakel13, Dirk Verellen14, Geert De Kerf15, Coen Hurkmans16. 1. Catharina Hospital, Eindhoven, the Netherlands. Electronic address: evelyn.d.jong@catharinaziekenhuis.nl. 2. University Hospital Zürich, Switzerland. Electronic address: Matthias.Guckenberger@usz.ch. 3. University Hospital Zürich, Switzerland. Electronic address: Nicolaus.Andratschke@usz.ch. 4. Medical University of Vienna, Austria. Electronic address: karin.dieckmann@akhwien.at. 5. Erasmus MC Cancer Institute, Rotterdam, the Netherlands. Electronic address: m.hoogeman@erasmusmc.nl. 6. Erasmus MC Cancer Institute, Rotterdam, the Netherlands. Electronic address: m.milder@erasmusmc.nl. 7. Aarhus University Hospital, Denmark. Electronic address: dittmoel@rm.dk. 8. Aarhus University Hospital, Denmark. Electronic address: tine.bisballe.nyeng@aarhus.rm.dk. 9. University Hospital Zürich, Switzerland. Electronic address: Stephanie.Tanadini-Lang@usz.ch. 10. Centre Oscar Lambret, Lille, France. Electronic address: E-Lartigau@o-lambret.fr. 11. Centre Oscar Lambret, Lille, France. Electronic address: t-lacornerie@o-lambret.fr. 12. Amsterdam University Medical Center, the Netherlands. Electronic address: s.senan@amsterdamumc.nl. 13. Amsterdam University Medical Center, the Netherlands. Electronic address: w.verbakel@amsterdamumc.nl. 14. Iridium Kankernetwerk, Antwerp University, Antwerp, Belgium. Electronic address: Dirk.Verellen@gza.be. 15. Iridium Kankernetwerk, Antwerp University, Antwerp, Belgium. Electronic address: Geert.DeKerf@gza.be. 16. Catharina Hospital, Eindhoven, the Netherlands. Electronic address: coen.hurkmans@catharinaziekenhuis.nl.
Abstract
BACKGROUND AND PURPOSE: In 2017 the ACROP guideline on SBRT for peripherally located early stage NSCLC was published. Later that year ICRU-91 about prescribing, recording and reporting was published. The purpose of this study is to quantify the current variation in prescription practice in the institutions that contributed to the ACROP guideline and to establish the link between the ACROP and ICRU-91 recommendations. MATERIAL AND METHODS: From each of the eight participating centres, 15 SBRT plans for stage I NSCLC were analyzed. Plans were generated following the institutional protocol, centres prescribed 3 × 13.5 Gy, 3 × 15 Gy, 3 × 17 Gy or 3 × 18 Gy. Dose parameters of the target volumes were reported as recommended by ICRU-91 and also converted to BED10Gy. RESULTS: The intra-institutional variance in D98%, Dmean and D2% of the PTV and GTV/ITV is substantially smaller than the inter-institutional spread, indicating well protocollised planning procedures are followed. The median values per centre ranged from 56.1 Gy to 73.1 Gy (D2%), 50.4 Gy to 63.3 Gy (Dmean) and 40.5 Gy to 53.6 Gy (D98%) for the PTV and from 57.1 Gy to 73.6 Gy (D2%), 53.7 Gy to 68.7 Gy (Dmean) and 48.5 Gy to 62.3 Gy (D98%) for the GTV/ITV. Comparing the variance in PTV D98% with the variance in GTV Dmean per centre, using an F-test, shows that four centres have a larger variance in GTV Dmean, while one centre has a larger variance in PTV D98% (p values <0.01). This shows some centres focus on achieving a constant PTV coverage while others aim at a constant GTV coverage. CONCLUSION: More detailed recommendations for dose planning and reporting of lung SBRT in line with ICRU-91 were formulated, including a minimum PTV D98% of 100 Gy BED10Gy and minimum GTV/ITV mean dose of 150 Gy BED10Gy and a D2% in the range of 60-70 Gy.
BACKGROUND AND PURPOSE: In 2017 the ACROP guideline on SBRT for peripherally located early stage NSCLC was published. Later that year ICRU-91 about prescribing, recording and reporting was published. The purpose of this study is to quantify the current variation in prescription practice in the institutions that contributed to the ACROP guideline and to establish the link between the ACROP and ICRU-91 recommendations. MATERIAL AND METHODS: From each of the eight participating centres, 15 SBRT plans for stage I NSCLC were analyzed. Plans were generated following the institutional protocol, centres prescribed 3 × 13.5 Gy, 3 × 15 Gy, 3 × 17 Gy or 3 × 18 Gy. Dose parameters of the target volumes were reported as recommended by ICRU-91 and also converted to BED10Gy. RESULTS: The intra-institutional variance in D98%, Dmean and D2% of the PTV and GTV/ITV is substantially smaller than the inter-institutional spread, indicating well protocollised planning procedures are followed. The median values per centre ranged from 56.1 Gy to 73.1 Gy (D2%), 50.4 Gy to 63.3 Gy (Dmean) and 40.5 Gy to 53.6 Gy (D98%) for the PTV and from 57.1 Gy to 73.6 Gy (D2%), 53.7 Gy to 68.7 Gy (Dmean) and 48.5 Gy to 62.3 Gy (D98%) for the GTV/ITV. Comparing the variance in PTV D98% with the variance in GTVDmean per centre, using an F-test, shows that four centres have a larger variance in GTVDmean, while one centre has a larger variance in PTV D98% (p values <0.01). This shows some centres focus on achieving a constant PTV coverage while others aim at a constant GTV coverage. CONCLUSION: More detailed recommendations for dose planning and reporting of lung SBRT in line with ICRU-91 were formulated, including a minimum PTV D98% of 100 Gy BED10Gy and minimum GTV/ITV mean dose of 150 Gy BED10Gy and a D2% in the range of 60-70 Gy.
Authors: Vitali Moiseenko; Jimm Grimm; Ellen Yorke; Andrew Jackson; Anthony Yip; Minh-Phuong Huynh-Le; Anand Mahadevan; Kenneth Forster; Michael T Milano; Jona A Hattangadi-Gluth Journal: Cureus Date: 2020-10-05
Authors: Ronnie Wing King Leung; Mark Ka Heng Chan; Chi-Leung Chiang; Matthew Wong; Oliver Blanck Journal: Radiat Oncol Date: 2020-05-29 Impact factor: 3.481
Authors: A Baydoun; H Chen; I Poon; S Badellino; R Dagan; D Erler; M C Foote; A V Louie; K J Redmond; U Ricardi; A Sahgal; T Biswas Journal: Clin Transl Radiat Oncol Date: 2021-10-26
Authors: L Wilke; C Moustakis; O Blanck; D Albers; C Albrecht; Y Avcu; R Boucenna; K Buchauer; T Etzelstorfer; C Henkenberens; D Jeller; K Jurianz; C Kornhuber; M Kretschmer; S Lotze; K Meier; P Pemler; A Riegler; A Röser; D Schmidhalter; K H Spruijt; G Surber; V Vallet; R Wiehle; J Willner; P Winkler; A Wittig; M Guckenberger; S Tanadini-Lang Journal: Strahlenther Onkol Date: 2021-07-01 Impact factor: 3.621